Every 10-Q that INTERPACE BIOSCIENCES INC (IDXG) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow IDXG and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IDXG filings page.
Interpace Biosciences, Inc. reported continued profitability for the quarter and six months ended June 30, 2026 while managing through the loss of reimbursement for its PancraGEN® pancreatic test. For the quarter, revenue was $9.1 million versus $9.2 million a year earlier, with income from continuing operations of $0.3 million compared with a loss of $0.5 million. For the six months, revenue was $18.2 million, down 12% from $20.7 million, but income from continuing operations remained solid at $1.1 million versus $1.2 million.
Cost controls improved profitability: gross margin from continuing operations rose to 63.6% for the first half of 2026, and sales and marketing expenses fell meaningfully after prior-year severance tied to PancraGEN®’s discontinuation. Adjusted EBITDA from continuing operations was $2.3 million for the first half. Cash from operations was $0.4 million and cash and cash equivalents were $2.7 million at June 30, 2026, with management stating these resources and forecasted receipts are expected to cover cash needs for the next twelve months.
Capital structure changed significantly: on January 20, 2026 all 47,000 shares of Series C Preferred Stock converted into 23,267,327 common shares, leaving 27,700,904 common shares outstanding at June 30, 2026. Two investors, Ampersand and 1315 Capital, together held about 84% of the common stock after conversion. The former Term Loan has been repaid, and the company is exploring strategic and financing alternatives and seeking an uplisting of its common stock to Nasdaq.
Interpace Biosciences reported lower revenue but remained profitable in the first quarter of 2026. Net revenue fell to $9.0 million from $11.5 million a year earlier, mainly because Medicare stopped reimbursing the discontinued PancraGEN test. Gross margin held at about 65%.
Net income decreased to $0.7 million from $1.6 million, while Adjusted EBITDA was $1.6 million versus $2.1 million. As of March 31, 2026, the company had $2.6 million in cash and $10.0 million in current assets against $4.0 million in current liabilities, and management believes available cash and forecast receipts will fund operations for at least 12 months.
In January 2026, all 47,000 shares of Series C Preferred Stock converted into about 23.3 million common shares, leaving 27,700,904 common shares outstanding. Two private equity investors now hold roughly 84% of the common stock. Interpace remains focused on its thyroid cancer tests ThyGeNEXT and ThyraMIR v2 and continues to evaluate financing and strategic alternatives, including a possible Nasdaq uplisting.
Interpace Biosciences (IDXG) reported Q3 results. Revenue was $8.756 million, down 29% from $12.295 million a year ago, reflecting the April 2025 loss of Medicare coverage for PancraGEN. Gross profit was $5.439 million. Operating income from continuing operations was $1.145 million versus $2.301 million, and net income was $0.911 million versus $1.676 million.
For the nine months, revenue was $29.504 million, down from $34.515 million; operating income was $2.507 million versus $6.047 million; net income was $1.918 million versus $4.821 million. The company recorded $0.7 million in severance and related costs tied to its restructuring plan. Cash and cash equivalents were $1.423 million as of September 30, 2025, with current assets of $9.130 million and current liabilities of $5.945 million. The BroadOak term loan balance was $1.0 million (fair value $0.977 million) with the maturity extended to December 31, 2025 and interest-only payments beginning July 1, 2025. Shares outstanding were 4,428,539 as of November 7, 2025.
Adjusted EBITDA was $1.263 million in Q3 and $3.735 million year-to-date. Management notes continued focus on cost controls, receivable collections, and financing or strategic alternatives following the PancraGEN coverage change.